Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs.

Oncology research and treatment - 1 Jan 2016

Ruwali Munindra, Dhawan Ankur, Pant Mohan C, Rahman Qamar, Khurana S M Paul, Parmar Devendra

Abstract excerpt

Head and neck squamous cell carcinoma (HNSCC) describes a wide range of malignant tumors which originate in the upper aerodigestive tract and have a multifactorial origin involving both genetic and lifestyle risk factors. The clinical management of head and neck cancer involves surgery, radiotherapy, and chemotherapy. With the advances in treatment strategies for HNSCC, newer targeted therapies are adding to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to Cytochrome P450 Family 2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Evidence-Based Medicine

Share to Glutathione Transferase

Share to Head and Neck Neoplasms

Share to Pharmacogenomic Variants

Share to Precision Medicine

Share to Squamous Cell Carcinoma of Head and Neck

Source

Identifiers

PMID: 27160276
DOI: 10.1159/000444608

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs.PMID 27160276Read ↗

CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer.Semantic proximity Read ↗

Genetic variations and head and neck cancer risks.Semantic proximity Read ↗

Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma.Semantic proximity Read ↗

Pharmacogenetics of Drugs Used in the Treatment of CancersSemantic proximity Read ↗

Polymorphism in cytochrome P450 2A6 and glutathione S-transferase P1 modifies head and neck cancer risk and treatment outcome.Semantic proximity Read ↗

Polymorphisms in drug-metabolizing enzymes and risk to head and neck cancer: evidence for gene-gene and gene-environment interaction.Semantic proximity Read ↗

CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients.Semantic proximity Read ↗

Impact of gene polymorphisms on toxicity and response rate in head and neck squamous cell carcinoma: a literature reviewSemantic proximity Read ↗

Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome.Semantic proximity Read ↗

Genetic susceptibility to head and neck squamous cell carcinoma.Semantic proximity Read ↗

Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer.Semantic proximity Read ↗

Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.